BlackRock
BXRX

BlackRock’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

BlackRock’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-797
Closed -$295 – 5561
2023
Q3 		$295 Hold
797
– – ﹤0.01% 5372
2023
Q2 		$932 Hold
797
– – ﹤0.01% 5407
2023
Q1 		$1.35K Hold
797
– – ﹤0.01% 5457
2022
Q4 		$2.53K Sell
797
-1
-0.1% -$6 ﹤0.01% 5580
2022
Q3 		$8K Sell
798
-1
-0.1% -$23 ﹤0.01% 5606
2022
Q2 		$27K Sell
799
-185
-19% -$8.65K ﹤0.01% 5519
2022
Q1 		$70K Buy
984
+31
+3% +$5.72K ﹤0.01% 5357
2021
Q4 		$292K Buy
953
+2
+0.2% +$1.25K ﹤0.01% 5011
2021
Q3 		$749K Buy
951
+14
+1% +$12.2K ﹤0.01% 4644
2021
Q2 		$996K Sell
937
-96
-9% -$126K ﹤0.01% 4521
2021
Q1 		$1.86M Buy
1,033
+909
+733% +$1.82M ﹤0.01% 4305
2020
Q4 		$175K Buy
124
+2
+2% +$4.09K ﹤0.01% 4497
2020
Q3 		$474K Sell
122
-1
-0.8% -$4.53K ﹤0.01% 4272
2020
Q2 		$711K Sell
123
-237
-66% -$1.14M ﹤0.01% 4136
2020
Q1 		$1.25M Sell
360
-8
-2% -$75.6K ﹤0.01% 3807
2019
Q4 		$3.56M Buy
+368
New +$3.14M ﹤0.01% 3600

BlackRock's BXRX Position: Q4 2023 in Review

BlackRock sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q4 2023, closing a stake of 797 shares — an estimated $295 sold.

BlackRock first reported a position in BXRX in Q4 2019 and held it in 16 quarters. The position peaked at $3.56M in Q4 2019. 2 funds tracked by Wall St. Rank hold BXRX as of Q4 2023.

  • BlackRock reported no remaining Baudax Bio, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • BlackRock sold 797 Baudax Bio, Inc. Common Stock shares in Q4 2023, an estimated $295.
  • BlackRock first reported a position in Baudax Bio, Inc. Common Stock in Q4 2019 and held it in 16 quarters.
  • BlackRock's Baudax Bio, Inc. Common Stock position peaked at $3.56M in Q4 2019.
  • 2 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q4 2023.

Based on BlackRock's 13F filing for Q4 2023, filed 13 Feb 2024.